Botanix Pharmaceuticals Limited · ASX:BOT
Botanix Pharmaceuticals — Shareholder Meeting (October 2021)
22 slides from Botanix Pharmaceuticals's shareholder meeting presentation, Oct 26, 2021
Slide 1: Investor Presentation October 2021
For personal use only Investor Presentation October 2021 www.botanixpharma.com
Slide 2: Botanix Pharmaceuticals: a leader in topical drug development
Botanix Pharmaceuticals: a leader in topical drug development Clinical stage dermatology company developing new treatments for common skin diseases and For personal use only infection, leveraging its novel delivery technology Permetrex ™ Pharmaceutical focus Leveraging novel skin delivery technology
Slide 3: Botanix: World Class Board and Management team
World class team Botanix: World Class Board and Management team For personal use only Board of Directors Vince Ippolito Matt Callahan Dr Bill Bosch Dr Stewart Washer President and Executive Chairman Executive Director Executive Director Director COO of Anacor and Medicis with 17 Serial founder a
Slide 4: Synthetic cannabinoids are well suited to treat skin diseases and infections
Pharmaceutical focused Synthetic cannabinoids are well suited to treat skin diseases and infections For personal use only Botanix’s studies show synthetic CBD to:1 Be safe and well tolerated Have broad anti-inflammatory properties Have a strong and consistent impact on skin lesions Have anti
Slide 5: Advanced late-stage pipeline
Pharmaceutical focus Advanced late-stage pipeline For personal use only Ph 1 Ph 1b Ph 2 Ph 3 Status BTX 1801 Positive results announced, Antimicrobial Phase 2 start 1Q 2022 BTX 1702 Underway – completion Rosacea planned by mid 2022 BTX 1503 Planning underway for Phase 3 Acne clinical studies Activel
Slide 6: Permetrex: skin delivery technology fuels pipeline potential
Topically driven PermetrexTM: skin delivery technology fuels pipeline potential Unique in delivering high doses of drug into the layers of the skin without using permeation For personal use only enhancers, preservatives, or irritating levels of alcohol / petroleum derivatives 1. Initial application
Slide 7: Target markets with significant annual revenues & unmet needs
Significant markets Target markets with significant annual revenues & unmet needs For personal use only Antimicrobial Specialised / Rosacea 100k patients Dermatologists ɤɨ M patients $0.5bn Sales 2 $1.9bn Sales 1 US Prescriber Acne Base 50M patients $5.1bn General Sales 3 Practitioners Preclinical P
Slide 8: Programs
Dermatology programs For personal use only 8 www.botanixpharma.com
Slide 9: BTX 1702: high impact of rosacea on patients and significant market opportunity
Dermatology BTX 1702: high impact of rosacea on patients and significant market opportunity For personal use only A rapidly growing market: Rosacea market projected to Papulopustular rosacea is a grow to US$2.6bn by 20253 highly visible chronic skin disease characterised by US$2.6bn redness (inflam
Slide 10: BTX 1702: Rosacea Phase 1b/2 study is underway
Dermatology BTX 1702: Rosacea Phase 1b/2 study is underway Improved data capture design with dose ranging over 8 week treatment period For personal use only Study design Study designed to enable Four dose groups, ~120 patients: Endpoints: increased data capture & – BTX 1702 high dose - twice d
Slide 11: BTX 1503: Acne in preparation for Phase 3 and future filing
Dermatology BTX 1503: Acne in preparation for Phase 3 and future filing Successful End-of-Phase 2 FDA meeting and completion of Rosacea BTX 1702 study (with higher For personal use only dosing and enhanced data capture) will inform final design for P3 Acne study Study update Sizable acne prescriptio
Slide 12: BTX 1204A: Meeting need for safe, non-steroid for chronic use in Atopic Dermatitis
Dermatology BTX 1204A: Meeting need for safe, non-steroid for chronic use in Atopic Dermatitis For personal use only Atopic Dermatitis Market ($B) Atopic dermatitis is one of the most common skin diseases1: • 2% - 3% of adults, 25% of children • 90% of patients are mild to moderate3 Patients see f
Slide 13: Atopic dermatitis – chronic inflammatory disease for both canines and humans
Dermatology Atopic dermatitis – chronic inflammatory disease for both canines and humans For personal use only Canines naturally and commonly develop a pruritic dermatitis that is clinically and immunologically extremely similar to human AD1 Dogs and humans with AD also have similar problems wit
Slide 14: BTX 1204A: Dermatitis data supports further development
Dermatology BTX 1204A: Dermatitis data supports further development Pilot canine study with higher dose and novel Permatrex™ formulation showed reduction itch and For personal use only lesions - dermatitis in canines and humans is clinically and immunologically very similar BTX 1204A: Pruritus (itch
Slide 15: BTX 1204A: Atopic dermatitis development strategy
Dermatology BTX 1204A: Atopic dermatitis development strategy Larger POC canine study underway1, will inform licensing in animal health & potential re-launch of For personal use only late-stage P2b clinical program in 2022 Proof of Concept Canine Study Planned pathway to approval Parameters Four d
Slide 16: Anti-microbial development update BTX 1801
Anti-microbial development update For personal use only BTX 1801
Slide 17: BTX 1801: Demonstrated clinical efficacy vs S. aureus in Phase 2a study
Antimicrobial BTX 1801: Demonstrated clinical efficacy vs S. aureus in Phase 2a study For personal use only Staphylococcus aureus (S. aureus or ‘staph’) is a common bacterium that lives on skin and in nasal passages. It can cause skin infection and serious or life- threatening blood stream infection
Slide 18: BTX 1801: Haemodialysis patients with central venous catheters at risk of bloodstream infections
Antimicrobial BTX 1801: Haemodialysis patients with central venous catheters at risk of bloodstream infections For personal use only Haemodialysis Replicates the functions of the kidneys in patients with kidney failure, by using a machine to filter and clean the blood Rationale for Infection is
Slide 19: BTX 1801: Clinical development moving quickly to meet need
Antimicrobial BTX 1801: Clinical development moving quickly to meet need Targeting nasal decolonisation of Staph in patients undergoing haemodialysis to reduce incidence of life threatening blood stream infections For personal use only FDA incentives provide accelerated Next Study development and in
Slide 20: Executing on key clinical milestones
Corporate Executing on key clinical milestones For personal use only Antimicrobial: BTX 1801 positive Phase 2a study results Positive results announced, further Phase 2 study start Q1 2022 Rosacea: BTX 1702 Phase 1b study start Recruitment currently underway, target completion mid 2022 Acne: B
Slide 21: Botanix Pharmaceuticals: a leader in topical drug development
Corporate Botanix Pharmaceuticals: a leader in topical drug development Clinical stage dermatology company developing new treatments for common skin diseases and For personal use only infection leveraging its novel delivery technology Permetrex ™ Developing novel skin delivery technology (Permetrex™
Slide 22: Disclaimer
DISCLAIMER For personal use only Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate, ”expect,” “intend,” “may,” “plan,” “predict,”
Botanix Pharmaceuticals — Shareholder Meeting (October 2021) on 6ix